Allergan’s Antitrust Deal With Restasis Payers Worth $30 Million

AbbVie Inc. subsidiary Allergan will pay about $30 million to resolve the remainder of a consolidated antitrust class action over its alleged scheme to delay generic versions of the dry-eye treatment Restasis, according to a federal court filing in Brooklyn.

The insurers and pension funds leading part of the lawsuit sought preliminary approval from Judge Nina Gershon for the $29,999,999.99 settlement on behalf of “end payers” that completely or partially covered consumer sales of the drug.

The Oct. 8 request comes about four months after Gershon paused the case while the two sides hammered out a final deal to end ...